HIV-1 Protease Inhibitors: Effective Against Malaria?
Protease inhibitors used to treat HIV-1 infection may also be effective for treatment or prevention of malaria, according to a study published in the December 1 issue of The Journal of Infectious Diseases, now available online. The study found protease inhibitors inhibited the growth of P. falciparum, the malaria parasite that causes most disease. These findings may also expose a previously unexplored vulnerability in the parasite that could lead to a new class of anti-malarial drug. While the effects of such drugs on co-infection need to be investigated, the study’s findings may be especially significant in sub-Saharan Africa and other areas of the developing world where there are high rates of HIV and malaria co-infection.
Scientists from the Queensland Institute of Medical Research tested the effects of the protease inhibitors saquinavir, ritonavir, nelfinavir, amprenavir, and indinavir, as well as the non-nucleoside reverse transcriptase inhibitor nevirapine, on a drug-resistant line of P. falciparum. Saquinavir, ritonavir, and indinavir all inhibited parasite growth in vitro at levels routinely achieved in human patients, with saquinavir and ritonavir showing the most potent effect on the parasite. Saquinavir was most effective in the study and was equally effective on chloroquine-sensitive and -resistant parasite lines, while nelfinavir and amprenavir did not demonstrate anti-malarial activity. The research builds on a previous study that demonstrated antiretroviral agents can reduce the adhesion of P. falciparum-infected erythrocytes to endothelial surfaces.
The authors believe that the antiretroviral protease inhibitors attack the malaria parasite in ways that current antimalarial treatments do not. While the mode of antimalarial action of the drugs was not uncovered in the study, the authors hypothesize that the antiretrovirals inhibit an aspartyl protease, which helps the parasite digest hemoglobin and is located on the food vacuole of the parasite. Further investigation may not only provide a better knowledge of how to treat co-infected patients with protease inhibitors, but could also lead to a new type of malaria drug that would target the parasite in novel ways.
The World Health Organization’s “3 by 5” program intends to treat three million HIV-infected people, primarily in the developing world, with antiretrovirals by the year 2005. The authors suggest that individuals treated under programs such as this may also gain an anti-parasitic benefit. At the same time, they acknowledge that their study does not address the concern that protease inhibitors may have immunological side effects that could hamper parasite removal.
The authors warn that the clinical application of their novel findings should be made with caution. They are currently carrying out further studies on the interactions of protease inhibitors and current antimalarial agents in order to optimize the drugs’ beneficial effects on both HIV and malaria infections.
Steve Baragona | EurekAlert!
The most recent press releases about innovation >>>
Die letzten 5 Focus-News des innovations-reports im Überblick:
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Mapping the interaction of a single atom with a single photon may inform design of quantum devices
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...